Intersect ENT, Inc.
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Thomas West
- Full Time Employees
- 433
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1555 Adams Dr Menlo Park CA United States of America 94025
- IPO Date
- Jul 24, 2014
- CIK
- 0001271214
- Website
- intersectent.com
- Similar Companies
- Business
- Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Company News
Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates
Orthofix Announces Appointment of Thomas A. West to Board of Directors
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intersect ENT, Inc.
Why Intersect ENT Shot 12% Higher on Friday
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT
Shareholder Alert: Ademi LLP investigates whether Intersect ENT, Inc. has obtained a Fair Price in its transaction with Medtronic
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
Intersect ENT Reports Second Quarter 2021 Financial Results
Medtronic to Acquire Intersect ENT
A Preview Of Intersect ENT's Earnings
Intersect ENT (XENT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT's Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis